AstraZeneca’s Lynparza meets primary endpoint in Phase 3 prostate cancer trial

AstraZeneca’s PARP inhibitor Lynparza was successful in improving progression free survival in a Phase 3 trial of patients with metastatic prostate cancer.

The drug met its primary endpoint in the Phase 3 PROfound  trial of men with metastatic castration-resistant prostate cancer (mCRPC) who have a *homologous recombination repair gene mutation (HRRm) and have progressed on prior treatment with new hormonal anticancer treatments (e.g. enzalutamide and abiraterone).

read more

Geen nieuws missen?
Volg de duizenden farma professionals die via e-mail lezen

Uw inschrijving is gelukt.